Generation and genetic modification of induced pluripotent stem cells

Expert Opinion on Biological Therapy

Volumn 10, Issue 7, 2010, Pages 1089-1103

  Schambach, Axel ^a   Cantz, Tobias ^a,b   Baum, Christopher ^a   Cathomen, Toni ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

Author keywords

Gene delivery systems; Induced pluripotent stem cells (iPSC); Reprogramming; Retroviral vectors; Small molecule compounds; Zinc finger nucleases

Indexed keywords

DNA; DYSTROPHIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYC PROTEIN; NUCLEASE; OCTAMER TRANSCRIPTION FACTOR 4; RETROVIRUS VECTOR; RNA; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; VALPROIC ACID; ZINC FINGER PROTEIN;

CELL DIFFERENTIATION; CELL NUCLEUS TRANSPLANTATION; CELL RENEWAL; DNA MODIFICATION; DUCHENNE MUSCULAR DYSTROPHY; DYSAUTONOMIA; EMBRYONIC STEM CELL; EPIGENETICS; FANCONI ANEMIA; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA A; HOMOLOGOUS RECOMBINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; SICKLE CELL ANEMIA; SOMATIC CELL; SOMATIC MUTATION;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; ESTERASES; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 77953354797     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.496775     Document Type: Review

References (129)

1. Graf T, Enver T. Forcing cells to change lineages. Nature 2009;10:587-594
2. Vierbuchen T, Ostermeier A, Pang ZP, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010;463(7284):1035-1041
3. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147
4. Wilmut I, Schnieke AE, McWhir J, et al. Viable offspring derived from fetal and adult mammalian cells. Nature 1997;385:810-813
5. Taranger CK, Noer A, Sorensen AL, et al. Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. Mol Biol Cell 2005;16:5719-5735
6. Tada M, Takahama Y, Abe K, et al. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr Biol 2001;11:1553-1558
7. Do JT, Scholer HR. Nuclei of embryonic stem cells reprogram somatic cells. Stem Cells 2004;22:941-949
8. Cantz T, Bleidissel M, Stehling M, et al. In vitro differentiation of reprogrammed murine somatic cells into hepatic precursor cells. Biol Chem 2008;389:889-896
9. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676
10. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872
11. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-1920
12. Kim JB, Sebastiano V, Wu G, et al. Oct4-induced pluripotency in adult neural stem cells. Cell 2009;136:411-419
13. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-384
14. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008;132:567-582
15. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007;1:39-49
16. Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003;113:643-655
17. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-956
18. Kim J, Chu J, Shen X, et al. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008;132:1049-1061
19. Lin CH, Lin C, Tanaka H, et al. Gene regulation and epigenetic remodeling in murine embryonic stem cells by c-Myc. PLoS One 2009;4:e7839
20. Knoepfler PS, Zhang XY, Cheng PF, et al. Myc influences global chromatin structure. EMBO J 2006;25:2723-2734
21. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-645
22. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317
23. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005;7:1074-1082
24. Stadtfeld M, Maherali N, Breault DT, et al. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008;2:230-240
25. Wernig M, Lengner CJ, Hanna J, et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol 2008;26:916-924
26. Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature 2009;460:49-52
27. Hanna J, Saha K, Pando B, et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009;462:595-601
28. Li W, Ding S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol Sci 2010;31:36-45
29. Utikal J, Polo JM, Stadtfeld M, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009;460:1145-1148
30. Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009;460:1132-1135
31. Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009;460:1140-1144
32. Li H, Collado M, Villasante A, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009;460:1136-1139
33. Marion RM, Strati K, Li H, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009;460:1149-1153
34. Ying QL, Wray J, Nichols J, et al. The ground state of embryonic stem cell self-renewal. Nature 2008;453:519-523
35. Silva J, Barrandon O, Nichols J, et al. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 2008;6:e253
36. Shi Y, Desponts C, Do JT, et al. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008;3:568-574
37. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008;26:795-797
38. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008;26:1269-1275
39. Bhutani N, Brady JJ, Damian M, et al. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010;463:1042-1047
40. Lyssiotis CA, Foreman RK, Staerk J, et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci USA 2009;106:8912-8917
41. Ichida JK, Blanchard J, Lam K, et al. A small-molecule inhibitor of Tgf-beta signaling replaces Sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009;5:491-503
42. Esteban MA, Wang T, Qin B, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010;6:71-79
43. Xu Y, Shi Y, Ding S. A chemical approach to stem-cell biology and regenerative medicine. Nature 2008;453:338-344
44. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-770
45. O'Malley J, Woltjen K, Kaji K. New strategies to generate induced pluripotent stem cells. Curr Opin Biotechnol 2009;20:516-521
46. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458:771-775
47. Carey BW, Markoulaki S, Hanna J, et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci USA 2009;106:157-162
48. Sommer CA, Stadtfeld M, Murphy GJ, et al. iPS cell generation using a single lentiviral stem cell cassette. Stem Cells 2009;27:543-549
49. Hotta A, Ellis J. Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. J Cell Biochem 2008;105:940-948
50. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992;89:5547-5551
51. Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766-1769
52. Brambrink T, Foreman R, Welstead GG, et al. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2008;2:151-159
53. Voelkel C, Galla M, Maetzig T, et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci USA 2010;107:7805-7810
54. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-977
55. Chang CW, Lai YS, Pawlik KM, et al. Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 2009;27:1042-1049
56. Yusa K, Rad R, Takeda J, et al. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 2009;6:363-369
57. Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-949
58. Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009;27:2667-2674
59. Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322:949-953
60. Gonzalez F, Barragan Monasterio M, Tiscornia G, et al. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci USA 2009;106:8918-8922
61. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324:797-801
62. Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009;85(8):348-362
63. Yakubov E, Rechavi G, Rozenblatt S, et al. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun 2010;394:189-193
64. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4:472-476
65. Paques F, Duchateau P. Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr Gene Ther 2007;7:49-66
66. Cathomen T, Joung JK. Zinc-finger nucleases: the next generation emerges. Mol Ther 2008;16:1200-1207
67. Carroll D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther 2008;15:1463-1468
68. Zou J, Maeder ML, Mali P, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009;5:97-110
69. Hockemeyer D, Soldner F, Beard C, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009;27:851-857
70. Cathomen T, Schambach A. Zinc positive: tailored genome engineering meets reprogramming. Gene Ther 2010;17:1-3
71. Mandell JG, Barbas CF III. Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res 2006;34(Web Server issue):W516-23
72. Sander JD, Zaback P, Joung JK, et al. Zinc Finger Targeter (ZiFiT): an engineered zinc finger/target site design tool. Nucleic Acids Res 2007;35(Web Server issue):W599-605
73. Maeder ML, Thibodeau-Beganny S, Osiak A, et al. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 2008;31:294-301
74. Maeder ML, Thibodeau-Beganny S, Sander JD, et al. Oligomerized pool engineering (OPEN): an 'open-source' protocol for making customized zinc-finger arrays. Nat Protoc 2009;4:1471-1501
75. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008;18:134-147
76. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007;25:1298-1306
77. Capecchi MR. Altering the genome by homologous recombination. Science 1989;244:1288-1292
78. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992;11:5071-5078
79. Bohne J, Cathomen T. Genotoxicity in gene therapy: an account of vector integration and designer nucleases. Curr Opin Mol Ther 2008;10:214-223
80. Nishikawa S, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 2008;9:725-729
81. Muller R, Lengerke C. Patient-specific pluripotent stem cells: promises and challenges. Nat Rev Endocrinol 2009;5:195-203
82. Rideout WM, Hochedlinger K, Kyba M, et al. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 2002;109:17-27
83. Kim JB, Zaehres H, Wu G, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008;454:646-650
84. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008;26:1276-1284
85. Haase A, Olmer R, Schwanke K, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009;5:434-441
86. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008;134:877-886
87. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-1923
88. Xu D, Alipio Z, Fink LM, et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009;106:808-813
89. Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460:53-59
90. Kazuki Y, Hiratsuka M, Takiguchi M, et al. Complete genetic correction of iPS cells from Duchenne muscular dystrophy. Mol Ther 2010;18(2):386-393
91. Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461:402-406
92. Maehr R, Chen S, Snitow M, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci USA 2009;106:15768-15773
93. Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009;5:584-595
94. Kiskinis E, Eggan K. Progress toward the clinical application of patient-specific pluripotent stem cells. J Clin Invest 2010;120:51-59
95. Taylor CJ, Bolton EM, Pocock S, et al. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 2005;366:2019-2025
96. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol 2008;26:739-740
97. hESC - Derived Therapies (GRNOPC1). Menolo Park, California: Geron Corporation 2010. Available from: http://www.geron.com/patients/ clinicaltrials/hESC.aspx [Last accessed 26 May 2010]
98. von Tigerstrom BJ. The challenges of regulating stem cell-based products. Trends Biotechnol 2008;26:653-658
99. Guideline on human cell-based medicinal products. London, UK: European Medicines Agency, Committee For Medicinal Product For Human Use (CHMP), 2008. Available from: http://www.ema. europa.eu/pdfs/human/cpwp/ 41086906enfin.pdf [Last accessed 26 May 2010]
100. Kaufman DS. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 2009;114:3513-3523
101. Colman A, Dreesen O. Pluripotent stem cells and disease modeling. Cell Stem Cell 2009;5:244-247
102. Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 2008;132:544-548
103. Hotta A, Cheung AY, Farra N, et al. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods 2009;6:370-376
104. Muller FJ, Laurent LC, Kostka D, et al. Regulatory networks define phenotypic classes of human stem cell lines. Nature 2008;455:401-405
105. Spits C, Mateizel I, Geens M, et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol 2008;26:1361-1363
106. Pick M, Stelzer Y, Bar-Nur O, et al. Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. Stem Cells 2009;27:2686-2690
107. Stadtfeld M, Apostolou E, Akutsu H, et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010;465:175-181
108. Liu H, Zhu F, Yong J, et al. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 2008;3:587-590
109. Esteban MA, Xu J, Yang J, et al. Generation of induced pluripotent stem cell lines from Tibetan miniature pig. J Biol Chem 2009;284:17634-17640
110. Li W, Wei W, Zhu S, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009;4:16-19
111. Liao J, Cui C, Chen S, et al. Generation of induced pluripotent stem cell lines from adult rat cells. Cell Stem Cell 2009;4:11-15
112. Esteban MA, Peng M, Deli Z, et al. Porcine induced pluripotent stem cells may bridge the gap between mouse and human iPS. IUBMB Life 2010;62:277-282
113. Tsai SY, Clavel C, Kim S, et al. Oct4 and Klf4 reprogram dermal papilla cells into induced pluripotent stem cells. Stem Cells 2010;28:221-228
114. Qin D, Gan Y, Shao K, et al. Mouse meningiocytes express Sox2 and yield high efficiency of chimeras after nuclear reprogramming with exogenous factors. J Biol Chem 2008;283:33730-33735
115. Ye Z, Zhan H, Mali P, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009;114:5473-5480
116. Choi KD, Yu J, Smuga-Otto K, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 2009;27:559-567
117. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-1221
118. Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-280
119. Osakada F, Ikeda H, Sasai Y, et al. Stepwise differentiation of pluripotent stem cells into retinal cells. Nat Protoc 2009;4:811-824
120. Sullivan GJ, Hay DC, Park IH, et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010;51:329-335
121. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-1193
122. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004;364:2181-2187
123. Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 2009:682-689
124. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142
125. Wilson CA, Cichutek K. The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Methods Mol Biol 2009;506:477-488
126. Wicke DC, Meyer J, Buesche G, et al. Gene therapy of Mpl deficiency: challenging balance between leukemia and pancytopenia. Mol Ther 2010:18:343-352
127. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724
128. Frank O, Rudolph C, Heberlein C, et al. Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 2004;104:3543-3549
129. Shi Y, Do JT, Desponts C, et al. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;2:525-528